Clinical Trial: Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Brief Summary: The specific aim of the study is to compare the safety and efficacy of a single administration of DaxibotulinumtoxinA for Injection versus placebo for managing plantar fasciitis.

Detailed Summary:
Sponsor: Revance Therapeutics, Inc.

Current Primary Outcome: Reduction in the visual analog scale (VAS) for pain for the foot [ Time Frame: 8 and 16 weeks ]

Original Primary Outcome: Same as current

Current Secondary Outcome: American Orthopaedic Foot and Ankle Score (AOFAS) [ Time Frame: 8 and 16 weeks ]

Original Secondary Outcome: Same as current

Information By: Revance Therapeutics, Inc.

Dates:
Date Received: April 27, 2017
Date Started: May 2017
Date Completion: December 2017
Last Updated: May 1, 2017
Last Verified: May 2017